What is an appropriate management plan for a 44-year-old woman with a history of anxiety who presents with bothersome perimenopausal symptoms (vaginal dryness, sleep disturbance, mood changes, palpitations, hot flashes, mental fogginess, occasional dizziness) and normal laboratory results?

Management Plan for Perimenopausal Symptoms in a 44-Year-Old Woman

For this 44-year-old woman with bothersome perimenopausal symptoms and no contraindications, initiate menopausal hormone therapy (MHT)—specifically estrogen-progestogen therapy (EPT) since she has an intact uterus—as this is the most effective treatment for her constellation of vasomotor, mood, sleep, and genitourinary symptoms 1.

Rationale for Hormone Therapy

This patient meets the ideal criteria for MHT initiation per the Endocrine Society guidelines 1:

• Age < 60 years (she is 44)
• < 10 years from menopause onset (she is perimenopausal)
• Bothersome vasomotor symptoms (hot flashes, night sweats)
• Additional climacteric symptoms that respond to estrogen (sleep disturbance, mood changes, vaginal dryness, mental fogginess)
• No contraindications (normal labs, no history of breast cancer, cardiovascular disease, stroke, VTE, or active liver disease)

The guideline explicitly states that estrogen therapy improves menopause-associated symptoms including vasomotor symptoms, genitourinary symptoms, sleep disturbance, menopause-associated anxiety and depressive symptoms, and arthralgias 1. EPT is specifically indicated for women with an intact uterus to prevent endometrial hyperplasia 1.

Why Hormone Therapy Over Other Options

While recent research suggests combination therapies (pharmacotherapy plus psychotherapy) may show favorable outcomes 2, and perimenopausal depression may be a distinct hormonal subtype 3, the Endocrine Society guideline takes precedence and establishes MHT as first-line therapy for women meeting these criteria 1. Her anxiety history does not contraindicate MHT—in fact, estrogen therapy specifically addresses menopause-associated anxiety and depressive symptoms 1.

The evidence shows that perimenopausal mood symptoms are often driven by hormonal fluctuations rather than being purely psychiatric 3, and notably, perimenopausal depression is often not responsive to conventional antidepressant management alone 3. This makes hormonal treatment the logical first approach.

Specific Treatment Plan

Initiate EPT with:

• Low-dose estrogen (oral, transdermal, or other route based on patient preference and cardiovascular risk profile)
• Continuous or cyclic progestogen to protect the endometrium
• Start at the lowest effective dose and titrate based on symptom response

Addressing Her Anxiety History

Her pre-existing anxiety requires consideration but does not preclude MHT. The guideline notes that anxiety, irritability, and depressive symptoms are associated with the menopause transition 1, and longitudinal studies now support an association between the menopause transition and both depressed mood and anxiety 1. MHT may actually improve her anxiety if it is hormonally mediated 1.

Monitoring and Follow-up

• Reassess symptoms in 4-6 weeks after initiation
• Adjust dose if symptoms persist
• Annual breast cancer risk assessment and cardiovascular risk evaluation
• Continue MHT as long as benefits outweigh risks and symptoms persist

Important Caveats

Exercise caution and avoid MHT if she develops:

• Unexplained vaginal bleeding (requires evaluation first)
• Cardiovascular events (stroke, TIA, MI, PE, VTE)
• Breast or endometrial cancer diagnosis
• Active liver disease
• Migraine with aura (use caution)

Alternative Options if MHT is Declined or Contraindicated

If she refuses MHT or develops contraindications 1, 4:

• SSRIs or SNRIs for vasomotor symptoms (avoid SSRIs if she ever takes tamoxifen)
• Gabapentin for hot flashes
• Cognitive behavioral therapy for vasomotor symptoms and sleep disturbances
• Vaginal moisturizers for genitourinary symptoms (noninferior to estrogen for vaginal dryness)

However, these are second-line options for a woman who is an ideal candidate for MHT 1.

What NOT to Do

Do not start with antidepressants as first-line treatment—her symptoms are primarily hormonal, and perimenopausal depression often does not respond to conventional antidepressants alone 3. Do not delay treatment with "watchful waiting"—her quality of life is already significantly impacted by multiple bothersome symptoms that have effective treatment available.